Prevalence and Risk Factors of Post-COVID-19 Condition in Adults and Children at 6 and 12 Months After Hospital Discharge: A Prospective, Cohort Study in Moscow (Stop COVID)

Pazukhina, Ekaterina, Andreeva, Margarita, Spiridonova, Ekaterina, Bobkova, Polina, Shikhaleva, Anastasia, El-Taravi, Yasmin, Rumyantsev, Mikhail, Gamirova, Aysylu, Bairashevskaia, Anastasiia, Petrova, Polina
et al (show 41 more authors) (2022) Prevalence and Risk Factors of Post-COVID-19 Condition in Adults and Children at 6 and 12 Months After Hospital Discharge: A Prospective, Cohort Study in Moscow (Stop COVID). [Preprint]

Access the full-text of this item by clicking on the Open Access link.


Background: Many people experience prolonged consequences of COVID-19, but studies assessing the prevalence of COVID-19 sequelae in adults and children have been performed in the absence of an agreed definition. Our objective was to investigate prevalence of post-COVID-19 condition (as per WHO definition), at 6- and 12-months follow-up, among previously hospitalised adults and children and to assess risk factors.<br><br>Methods: Prospective cohort study of children and adults with confirmed COVID-19 in Moscow who were hospitalised between April and August, 2020. Two follow-up telephone interviews, using the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) Long-term Follow-up Study follow-up survey, were performed at 6 and 12 months after hospital discharge.<br><br>Findings: 1013 of 2509 (40%) of adults and 360 of 849 (42%) of children discharged qualified for analyses – participating in both the 6- and 12-month follow-ups. Post-COVID-19 condition prevalence was 50% (95%CI 47 – 53) in adults and 20% (95%CI 16 - 24) in children at 6 months, with decline to 34% (95%CI 31 - 37) and 11% (95%CI 8 - 14), respectively, at 12 months. In adults, female sex was associated with post-COVID-19 condition at 6- and 12-month follow-up (OR 2.04, 95% CI 1.57 to 2.65) and (OR 2.04, 1.54 to 2.69), respectively. Pre-existing hypertension (OR 1.42, 1.04 to 1.94) was associated with post-COVID-19 condition at 12 months. In children, neurological comorbidities were associated with post-COVID-19 condition both at 6 months (OR 4.38, 1.36 to 15.67) and 12 months (OR 8.96, 2.55 to 34.82) while allergic respiratory diseases were associated at 12 months (OR 2.66, 1.04 to 6.47).<br><br>Interpretation: Although prevalence of post-COVID-19 condition declined one year after discharge, one in three adults and one in ten children experienced ongoing sequelae. In adults, females and persons with pre-existing hypertension, and in children, persons with neurological comorbidities or allergic respiratory diseases are at higher risk of post-COVID-19 condition.<br><br>Funding: UK Embassy in Moscow.<br><br>Declaration of Interest: Daniel Munblit and Dale M Needham are among co-leads of the project aiming to develop of Core Outcome Set for Post-COVID-19 condition as a part of the PC-COS project team. Malcolm G Semple reports grant funding from the National Institute of Health Research UK, Medical Research Council UK and Health Protection Research Unit in Emerging & Zoonotic Infections, University of Liverpool. He declares that he is an independent external and non-remunerated member of Pfizer’s External Data Monitoring Committee for their mRNA vaccine program(s), a Chair of Infectious Disease Scientific Advisory Board at Integrum Scientific LLC, Greensboro, NC, USA and Director at MedEx Solutions Ltd. He also reports minority ownership of stock or stock options of Integrum Scientific LLC, Greensboro, NC, USA and majority ownership of stock or stock options of MedEx Solutions Ltd. He acknowledges gift to the Institution of Clinical Trial Investigational Medicinal Product without encumbrance and distribution of same to trial sites from Chiesi Farmaceutici S.p.A. Matthew Greenhawt is a consultant for Aquestive; is a member of physician/medical advisory boards for DBV Technologies, Sanofi/Regeneron, Genentech, Nutricia, Novartis, Acquestive, Allergy Therapeutics, AstraZeneca, ALK-Abello, Pfizer, US World Meds, Allergenis, Aravax, and Prota, all unrelated to vacines/vaccine development or COVID-19 treatment; is an unpaid member of the scientific advisory council for the National Peanut Board and medical advisory board of the International Food Protein Induced Enterocolitis Syndrome Association; is a member of the Brighton Collaboration Criteria Vaccine Anaphylaxis 2.0 working group; is the senior associate editor for the Annals of Allergy, Asthma, and Immunology, and is member of the Joint Taskforce on Allergy Practice Parameters. He has received honorarium for lectures from ImSci and MedLearningGroup, and multiple state/local allergy societies. He received past research support ending in 2020 from the Agency for Healthcare Quality and Research (K08-HS024599). Jon Genuneit is project manager of unrestricted research grants by Danone Nutricia Research on the composition of breast milk to the institutions Ulm University and Leipzig University, both Germany. Other authors declare that they have no competing interests.<br><br>Ethical Approval: This study was approved by the Sechenov University Local Ethics Committee on April 22, 2020 (protocol number 08–20, protocol amendment enabling serial follow-up of the cohort was approved on November 13, 2020) and Moscow City Independent Ethics Committee (abbreviate 1, protocol number 74).

Item Type: Preprint
Additional Information: Source info: LANGLH-D-22-00210
Uncontrolled Keywords: COVID-19, COVID-19 sequalae, Long COVID, Post-Acute Sequelae of SARS-CoV-2 infection, PASC, post-COVID-19 condition, outcomes, Core Outcome Set.
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Infection, Veterinary and Ecological Sciences
Depositing User: Symplectic Admin
Date Deposited: 17 May 2022 07:41
Last Modified: 24 Mar 2023 10:26
DOI: 10.2139/ssrn.4020142
Open Access URL: